The role of perfusion data.
The use of a thrombolytic agent, whether streptokinase, t-PA, or APSAC, clearly has a profound benefit in reducing mortality when used in the early hours following an acute myocardial infarction. The reasons for this benefit in mortality are unexplained by early patency rates alone. The choice of one thrombolytic agent over another ultimately must rest on the results of randomized studies directly comparing them, with mortality as the end-point. Hopefully, GISSI-II and ISIS-III will give us these answers.